We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop New Respiratory Medicines

By Biotechdaily staff writers
Posted on 16 Jan 2003
An alliance to develop and commercialize medicines containing long-acting beta2 agonists (LABA) for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) has been announced by Theravance, Inc. More...
(South San Francisco, CA, USA; www.theravance.com) and GlaxoSmithKline plc (London, UK).

Under the terms of the agreement, the LABA compounds from GSK and Theravance will be pooled for development. A joint steering committee will be formed to optimize the development of the compounds and their time to market. GSK will have the responsibility to develop and commercialize one or more of the compounds, utilizing its proprietary drug delivery technology. GSK will have exclusive worldwide manufacturing and commercialization rights. Two compounds are already in phase 1 studies.

Theravance will receive an initial US$50 million from GSK, milestone payments, and royalties. GSK will also receive milestone payments based on its compounds reaching approval and launch. "We are eager to develop the compounds pooled by Theravance and ourselves with the objective of providing the next generation of respiratory medicines,” said Tachi Yamada, chairman, research and development, GSK.






Related Links:
Theravance
GlaxoSmithKline

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Immunofluorescence Analyzer
IFA System
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: An elevated neutrophil-to-lymphocyte ratio (NLR), a rato easily obtained from a routine blood count, was associated with both short- and long-term Alzheimer’s risk (photo credit: 123RF)

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.